An aedes aegypti mosquito
Apr 28, 2014
Amid criticism, Brazil this month gave the OK to its first commercial release of genetically modified mosquitoes in an effort to combat dengue fever.
The World Health Organization estimates that dengue, whose main vector is the aedes aegypti mosquito, threatens over 40% of the world's population, with 2.35 million cases of the infection reported in 2013 in the Americas alone.
GM aedes aegypti mosquitoes were developed by British biotechnology company Oxitec, which has had a years-long project underway in Brazil. The male mosquitoes are engineered so that when they reproduce with the biting females in the wild their offspring die before they reach adulthood, theoretically decreasing the population and thereby curbing the sometimes fatal infection.
Some environmental and civil society groups issued a statement warning that not enough is known about the human health and environmental consequences of the GM mosquitoes to warrant their commercial release.
"There are no data showing that this GM mosquito actually reduces dengue incidence," stated Gabriel Fernandes, advisor with the Brazilian ecological organization AS-PTA.
"A desperate desire to prop up British biotech and reward venture capital investors should not blind the UK and Brazilian governments to the risks of this technology," added Dr. Helen Wallace, Director of public interest group GeneWatch UK.
The statement goes on to warn that the experiment could lead to an increase in the number Asian Tiger mosquitoes, which also carry dengue, and adds that there aren't published tests showing the safety for a human getting bit by a female mosquito that has been accidentally modified or for wildlife swallowing any GM mosquito.
Panama is slated to carry out field trials of the same GM mosquito this year, while potential plans to release them in the Florida Keys have been denounced as "dangerously misguided."
Climate change will likely cause tropical diseases like dengue to spread, which could provide a profit-making opportunity for companies like Oxitec.
________________
Why Your Ongoing Support Is Essential
Donald Trump’s attacks on democracy, justice, and a free press are escalating — putting everything we stand for at risk. We believe a better world is possible, but we can’t get there without your support. Common Dreams stands apart. We answer only to you — our readers, activists, and changemakers — not to billionaires or corporations. Our independence allows us to cover the vital stories that others won’t, spotlighting movements for peace, equality, and human rights. Right now, our work faces unprecedented challenges. Misinformation is spreading, journalists are under attack, and financial pressures are mounting. As a reader-supported, nonprofit newsroom, your support is crucial to keep this journalism alive. Whatever you can give — $10, $25, or $100 — helps us stay strong and responsive when the world needs us most. Together, we’ll continue to build the independent, courageous journalism our movement relies on. Thank you for being part of this community. |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Amid criticism, Brazil this month gave the OK to its first commercial release of genetically modified mosquitoes in an effort to combat dengue fever.
The World Health Organization estimates that dengue, whose main vector is the aedes aegypti mosquito, threatens over 40% of the world's population, with 2.35 million cases of the infection reported in 2013 in the Americas alone.
GM aedes aegypti mosquitoes were developed by British biotechnology company Oxitec, which has had a years-long project underway in Brazil. The male mosquitoes are engineered so that when they reproduce with the biting females in the wild their offspring die before they reach adulthood, theoretically decreasing the population and thereby curbing the sometimes fatal infection.
Some environmental and civil society groups issued a statement warning that not enough is known about the human health and environmental consequences of the GM mosquitoes to warrant their commercial release.
"There are no data showing that this GM mosquito actually reduces dengue incidence," stated Gabriel Fernandes, advisor with the Brazilian ecological organization AS-PTA.
"A desperate desire to prop up British biotech and reward venture capital investors should not blind the UK and Brazilian governments to the risks of this technology," added Dr. Helen Wallace, Director of public interest group GeneWatch UK.
The statement goes on to warn that the experiment could lead to an increase in the number Asian Tiger mosquitoes, which also carry dengue, and adds that there aren't published tests showing the safety for a human getting bit by a female mosquito that has been accidentally modified or for wildlife swallowing any GM mosquito.
Panama is slated to carry out field trials of the same GM mosquito this year, while potential plans to release them in the Florida Keys have been denounced as "dangerously misguided."
Climate change will likely cause tropical diseases like dengue to spread, which could provide a profit-making opportunity for companies like Oxitec.
________________
Amid criticism, Brazil this month gave the OK to its first commercial release of genetically modified mosquitoes in an effort to combat dengue fever.
The World Health Organization estimates that dengue, whose main vector is the aedes aegypti mosquito, threatens over 40% of the world's population, with 2.35 million cases of the infection reported in 2013 in the Americas alone.
GM aedes aegypti mosquitoes were developed by British biotechnology company Oxitec, which has had a years-long project underway in Brazil. The male mosquitoes are engineered so that when they reproduce with the biting females in the wild their offspring die before they reach adulthood, theoretically decreasing the population and thereby curbing the sometimes fatal infection.
Some environmental and civil society groups issued a statement warning that not enough is known about the human health and environmental consequences of the GM mosquitoes to warrant their commercial release.
"There are no data showing that this GM mosquito actually reduces dengue incidence," stated Gabriel Fernandes, advisor with the Brazilian ecological organization AS-PTA.
"A desperate desire to prop up British biotech and reward venture capital investors should not blind the UK and Brazilian governments to the risks of this technology," added Dr. Helen Wallace, Director of public interest group GeneWatch UK.
The statement goes on to warn that the experiment could lead to an increase in the number Asian Tiger mosquitoes, which also carry dengue, and adds that there aren't published tests showing the safety for a human getting bit by a female mosquito that has been accidentally modified or for wildlife swallowing any GM mosquito.
Panama is slated to carry out field trials of the same GM mosquito this year, while potential plans to release them in the Florida Keys have been denounced as "dangerously misguided."
Climate change will likely cause tropical diseases like dengue to spread, which could provide a profit-making opportunity for companies like Oxitec.
________________
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.